Palatin Technologies (PTN) Assets Average (2011 - 2026)
Palatin Technologies' (PTN) quarterly Assets Average came in at $15.6 million in Q1 2026, up 287.55% YoY from $4.0 million in Q1 2025, and up 17.37% on a QoQ basis from $13.3 million in Q4 2025.
Palatin Technologies (PTN) Assets Average (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 14 years of Assets Average data on file, last reported at $15.6 million in Q1 2026.
- Quarterly Assets Average rose 287.55% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.6 million (up 287.55% YoY) and the FY2025 annual result came in at $7.0 million, down 51.16% from the prior year.
- Assets Average climbed to $15.6 million in Q1 2026, from $13.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $48.4 million in Q1 2022 to a low of $3.5 million in Q2 2025.
- A 5-year average of $17.9 million and a median of $13.3 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average slumped 68.85% — and 2026, when it surged 287.55%.
- Tracing PTN's Assets Average over 5 years: stood at $29.8 million in 2022, then slumped by 58.4% to $12.4 million in 2023, then tumbled by 68.85% to $3.9 million in 2024, then soared by 243.58% to $13.3 million in 2025, then grew by 17.37% to $15.6 million in 2026.
- The last three Assets Average figures came in at $15.6 million (Q1 2026), $13.3 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - | 15.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.58 Mn |
| Dec 31, 2025 | 13.27 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 7.08 Mn |
| Jun 30, 2024 | 11.07 Mn |
| Mar 31, 2024 | 12.48 Mn |
| Dec 31, 2023 | 12.40 Mn |
| Sep 30, 2023 | 14.59 Mn |
| Jun 30, 2023 | 21.77 Mn |
| Mar 31, 2023 | 28.79 Mn |
| Dec 31, 2022 | 29.81 Mn |
| Sep 30, 2022 | 31.86 Mn |
| Jun 30, 2022 | 39.94 Mn |
| Mar 31, 2022 | 48.41 Mn |
| Dec 31, 2021 | 56.36 Mn |
| Sep 30, 2021 | 63.51 Mn |
| Jun 30, 2021 | 74.08 Mn |